Abstract:The VSVMT‐S2P vaccine candidate, featuring a SARS‐CoV‐2 pre‐fusion state spike protein mutant, is safe in healthy and immunocompromised animals. With only single inoculation via various routes of administration, VSVMT‐S2P can stimulate effective and comprehensive immune responses in vivo, especially via the intramuscular route. The single‐cycle Vesicular Stomatitis Virus can be a promising vaccine platform for SARS‐CoV‐2 immunogen delivery. The goal of the next‐generation COVID‐19 vaccine is to provide rapid respiratory tract protection with a single dose. Circulating antibodies do not protect the olfactory mucosa from viral infection, necessitating localized mucosal immunization. Live attenuated vesicular stomatitis virus (VSVMT)‐based COVID‐19 vaccines effectively stimulate mucosal immunity in animals, though safety concerns remain, particularly in immunocompromised populations. A viral vector capable of single‐cycle replication may face less stringent regulatory requirements. A replication‐defective VSVMT is developed with its G protein replaced by a SARS‐CoV‐2 spike protein (S) mutant, where residues K986 and V987 are substituted by prolines (S2P). This studies show that single‐cycle VSVMT encoding Omicron subvariant S2P (VSVMT‐S2P) is safe in both healthy and immunocompromised animals treated with cyclophosphamide (CP). Significant antibody and T‐cell responses against the spike protein are observed in VSVMT‐S2P vaccinated healthy animals. Intramuscular VSVMT‐S2P administration induces neutralizing antibody responses comparable to those from replication‐competent VSVMT‐S. In immunocompromised animals, lower and delayed immune responses are observed. Thus, single‐cycle M‐protein mutated VSV offers a safe and effective platform for SARS‐CoV‐2 immunogen delivery. Remarkably, replication‐competent VSVMT‐S caused no pathogenicity and elicited potent mucosal immunity via intranasal administration, highlighting its potential as a mucosal COVID‐19 vaccine.

A Vesicular Stomatitis Virus-Based Mucosal Vaccine Promotes Dendritic Cell Maturation and Elicits Preferable Immune Response Against Coxsackievirus B3 Induced Viral Myocarditis

Pathogenicity and Immunogenicity of Recombinant Methyltransferase-Defective Vesicular Stomatitis Virus

Mucosal Immunization with High-Mobility Group Box 1 in Chitosan Enhances DNA Vaccine-Induced Protection Against Coxsackievirus B3-Induced Myocarditis

M Cell-Targeting Strategy Facilitates Mucosal Immune Response and Enhances Protection Against CVB3-induced Viral Myocarditis Elicited by Chitosan-Dna Vaccine.

An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge

Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.

Enhanced Resistance to Coxsackievirus B3-Induced Myocarditis by Intranasal Co-Immunization of Lymphotactin Gene Encapsulated in Chitosan Particle

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Exosome co-delivery of a STING agonist augments immunogenicity elicited by CVB3 VP1 vaccine via promoting antigen cross-presentation of CD8 + DCs

Robust Systemic and Mucosal Immune Responses to Coxsackievirus B3 Elicited by Spider Silk Protein Based Nanovaccines Via Subcutaneous Immunization

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.

Incorporation of a Bi-Functional Protein FimH Enhances the Immunoprotection of Chitosan-Pvp1 Vaccine Against Coxsackievirus B3-induced Myocarditis.

Assessment of Single‐Cycle M‐Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS‐CoV‐2 Immunogen Delivery

Exosome-based Delivery of VP1 Protein Conferred Enhanced Resistance of Mice to CVB3-induced Viral Myocarditis.

Virus-Mimetic Extracellular-Vesicle Vaccine Boosts Systemic and Mucosal Immunity via Immune Recruitment.

An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis By Cvb3 Vp1 Vaccine

Modulation of Immunogenicity and Immunoprotection of Mucosal Vaccine Against Coxsackievirus B3 by Optimizing the Coadministration Mode of Lymphotactin Adjuvant

Enhancement of the mucosal immune responses and prophylactic effect of a novel coxsackievirus B3-specific mucosal DNA vaccine by co-administration of lymphotactin

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV MT ) in golden syrian hamster

Prophylaxis of CVB3-induced Myocarditis by Intranasal Immunization with Chitosan-pcDNA3-VP1 Vaccine

Mechanism of Enhanced Viral-Myocarditis-prophylactic Effect of a Novel Coxsackievirus B3 Mucosal Vaccine by LTN Adjuvant